Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Doses First Patient In Its ASCENTRA-UC Phase 2b Clinical Trial Evaluating PALI-2108 In ~204 Patients With Moderately To Severely Active Ulcerative Colitis; 12-Week Topline Results Expected In Q4 2027

Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026

Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated

HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026

Palisade Bio Highlights PALI-2108 Clinical And Translational Findings In 5 ACG 2026 Presentations

Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026

Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD

Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

A treatment update for ulcerative colitis and Crohn’s disease is coming Sept. 23.

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?